Methylphenidate is a Schedule II stimulant for ADHD and narcolepsy that inhibits dopamine and norepinephrine reuptake. Structurally distinct from amphetamines, it is not detected by amphetamine immunoassays and does not cross-react with them, so confirming its use requires LC-MS/MS for methylphenidate and its major metabolite ritalinic acid.1
Because methylphenidate is invisible to amphetamine screens, an adherent patient can appear negative on a stimulant immunoassay, and misuse can go undetected. Targeted testing for methylphenidate and ritalinic acid documents adherence or use.2
LC-MS/MS measures methylphenidate and ritalinic acid, its inactive major metabolite (about 80% of the dose). Because it does not cross-react with amphetamine assays, targeted testing is the only way to confirm methylphenidate use.3 Ordering can confirm adherence, verify elimination before a new agent, or check for misuse.4
Confirms methylphenidate use. Methylphenidate and/or ritalinic acid indicates use within roughly 1 to 2 days.
Not from an amphetamine screen. A positive here comes from targeted testing, not the amphetamine immunoassay.
Ritalinic acid is the main marker. Most of the dose appears as this inactive metabolite.4
Short window. Detection is about 1 to 2 days; a negative may reflect timing.
Amphetamine screen is irrelevant. Its negativity says nothing about methylphenidate; only targeted testing does.
Timing and cutoff. Absence may reflect timing of last use or levels below the cutoff.
Methylphenidate analytes measured on definitive testing.
| Metabolite | Clinical Significance |
|---|---|
| Methylphenidate (parent) | Short half-life (~2 to 3 h); a small urinary fraction. |
| Ritalinic acid | Inactive major metabolite; ~80% of the dose; primary urine marker. |